ICH E6(R3) is the revised version of the international Good Clinical Practice (GCP) guideline, developed through the International Council for Harmonisation (ICH). GCP is the ethical and scientific quality standard for designing, conducting, recording and reporting clinical trials that involve human participants. The R3 revision modernises the guideline around quality-by-design, risk-based approaches and flexibility for contemporary trial designs and data sources. This article is a neutral explainer and not clinical, regulatory or legal advice.
What Good Clinical Practice is
GCP exists to protect the rights, safety and wellbeing of trial participants and to ensure that trial data are credible and reliable. It sets expectations for ethics oversight, informed consent, the responsibilities of sponsors and investigators, documentation, and data integrity. Regulators around the world reference ICH GCP, which is why a revision to the core guideline matters internationally. For the wider context, see our overview of clinical-trials regulation and the focused explainer on Good Clinical Practice.
Why GCP needed modernising
The previous version, E6(R2), added an addendum to a guideline whose structure dated to the 1990s. Since then, clinical research has changed: trials use electronic data systems, decentralised and remote elements, real-world and diverse data sources, and increasingly complex designs. The earlier text, written for a more uniform model of site-based trials, did not always map cleanly onto these newer approaches. E6(R3) was developed to be more principles-based and adaptable, so that the same quality expectations can apply across a wider range of trial types.
Quality-by-design: building quality in
A central theme of E6(R3) is quality-by-design (QbD): the idea that quality should be designed into a trial from the start rather than inspected in afterwards. Under this thinking, sponsors identify the factors that are truly critical to quality — the aspects of a trial that, if compromised, would undermine participant safety or the reliability of the results — and focus attention and resources there.
- Critical-to-quality factors: the elements that genuinely matter for safety and reliability.
- Proportionate effort: attention concentrated where the risk to those factors is greatest.
- Avoiding low-value activity: not treating every data point and process as equally important.
The practical implication is fewer one-size-fits-all checklists and more deliberate judgement about where rigour adds value.
Risk-based and proportionate
Closely related is the risk-based orientation that runs through the guideline. Rather than prescribing identical, exhaustive procedures for every trial, E6(R3) emphasises identifying, assessing and managing risks in proportion to their importance. This extends to monitoring: risk-based monitoring focuses oversight on the data and processes most likely to affect participant safety and result credibility, which may combine on-site and centralised approaches.
This proportionality is intended to make trials both more efficient and more robust, by concentrating effort where it protects participants and data integrity most.
Flexibility for modern trials and data
E6(R3) is written to accommodate a broader range of trial designs and data sources, including the use of varied technologies and the realities of decentralised elements. By framing requirements in terms of underlying principles and outcomes rather than rigid prescriptions, the guideline aims to remain relevant as methods evolve. Throughout, the emphasis on data integrity and a clear, reliable record remains central — modern tools do not relax the expectation that data be attributable, legible, contemporaneous, original and accurate.
Participant protection stays at the heart of the guideline. Informed consent, ethics oversight and the duty of care to participants are reaffirmed, not diluted, by the modernisation. For neutral definitions of related terms, see our standards dictionary.
Roles, responsibilities and the structure of the guideline
E6(R3) restates the responsibilities of the main parties in a trial. Sponsors are responsible for the overall quality system, trial design, risk management and oversight, including oversight of any parties to whom activities are delegated. Investigators are responsible for the conduct of the trial at their site, the care of participants, informed consent and the integrity of the data they generate. The guideline is structured around principles supported by more detailed expectations, with the intent that the principles guide judgement when specific situations are not spelled out.
This principles-first structure is a deliberate response to the pace of change in clinical research. By anchoring expectations in durable principles — participant protection and reliable results — rather than in an exhaustive list of procedures, the guideline is intended to remain applicable as trial methods and technologies continue to evolve.
What it means in practice
For sponsors, investigators and clinical-operations teams, E6(R3) signals a shift in mindset: from procedure-led compliance toward thoughtful, risk-proportionate quality management tailored to each trial. Organisations generally review their quality systems, monitoring strategies and standard operating procedures to align with the principles-based approach. Teams often revisit how they document critical-to-quality factors, how they justify monitoring intensity, and how they evidence oversight of delegated activities. Regulators, in turn, adopt the revised guideline into their own frameworks, so the practical timing of when E6(R3) applies in a given country depends on that jurisdiction’s adoption process. Sponsors operating across multiple regions therefore track adoption status region by region, since the same global guideline may take legal effect at different times in different jurisdictions, and transitional arrangements may govern trials already underway when a region adopts the revised text.
The essence of E6(R3) is that good clinical practice is achieved by designing quality in, focusing on what is critical, and managing risk proportionately — applied flexibly across the diverse trials of today. The authoritative text is published by ICH, and readers should consult the official guideline and adopting regulators for binding detail. Our EU Clinical Trials Regulation explainer describes how one major jurisdiction frames trial conduct alongside these GCP principles.